Expanding its offering of passive safety devices to protect both clinicians and patients from needlestick injuries (NSIs), B. Braun Medical Inc. (B. Braun) recently announced that the Food and Drug Administration (FDA) granted 510(k) clearance of the companys Introcan Safety® 3 Closed IV Catheter, the next generation of B. Brauns Introcan Safety® IV Catheter. B. Braun made the announcement during the Association for Vascular Access 2011 annual scientific meeting in San Jose, Calif. in early October.
"Recent research confirms passive safety engineered devices are most effective for needlestick injury prevention," says Tom Sutton, vice president of vascular ccess and IV systems for B. Braun Medical Inc. "The Introcan Safety® 3 is designed to provide clinicians with not only an effective passive needlestick safety device, but also an added layer of safety and control with a bidirectional blood control valve to aid in the prevention of blood exposure each time the device is accessed."
The Introcan Safety® 3 features all elements of B. Brauns existing and proven Introcan Safety® IV Catheter. From insertion to advancing the catheter to needle removal, the Introcan Safety® 3 is designed to help protect clinicians and patients from NSIs as the device cannot be bypassed or activated inadvertently.
B. Brauns Introcan Safety® 3 will provide protection through Passive Safety Needle Shield to aid in the prevention of NSIs; Multiple Access Blood Control Valve to aid in the prevention of blood exposure; and Integrated Stabilization Platform to improve catheter stability and minimize movement within the vessel
For more information, visit www.introcansafety.bbraunusa.com or call (800) 227-2862.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.